Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TNO155 |
Trade Name | |
Synonyms | TNO-155|TNO 155 |
Drug Descriptions |
TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent tumor cell growth (PMID: 38032104, Cancer Res (2022) 82 (12_Supplement): 1054). |
DrugClasses | SHP2 Inhibitor 20 |
CAS Registry Number | NA |
NCIT ID | C139559 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Adagrasib + TNO155 | Adagrasib TNO155 | 0 | 1 |
BI-3406 + TNO155 | BI-3406 TNO155 | 0 | 0 |
Ceritinib + TNO155 | Ceritinib TNO155 | 2 | 0 |
Crizotinib + TNO155 | Crizotinib TNO155 | 2 | 0 |
Dabrafenib + LTT462 + TNO155 | Dabrafenib LTT462 TNO155 | 0 | 1 |
Dabrafenib + TNO155 + Trametinib | Dabrafenib TNO155 Trametinib | 0 | 1 |
Entrectinib + TNO155 | Entrectinib TNO155 | 0 | 0 |
JDQ443 + Spartalizumab + TNO155 | JDQ443 Spartalizumab TNO155 | 0 | 0 |
JDQ443 + Tislelizumab + TNO155 | JDQ443 TNO155 Tislelizumab | 0 | 1 |
JDQ443 + TNO155 | JDQ443 TNO155 | 0 | 1 |
Lorlatinib + TNO155 | Lorlatinib TNO155 | 2 | 0 |
MRTX-1133 + TNO155 | MRTX-1133 TNO155 | 0 | 0 |
MRTX1257 + TNO155 | MRTX1257 TNO155 | 0 | 0 |
Osimertinib + TNO155 | Osimertinib TNO155 | 0 | 0 |
Poziotinib + TNO155 | Poziotinib TNO155 | 0 | 0 |
Ribociclib + TNO155 | Ribociclib TNO155 | 0 | 1 |
Sotorasib + TNO155 | Sotorasib TNO155 | 0 | 1 |
Spartalizumab + TNO155 | Spartalizumab TNO155 | 0 | 1 |
TNO155 | TNO155 | 4 | 1 |